scholarly journals Artificial Intelligence in Medical Imaging of the Breast

2021 ◽  
Vol 11 ◽  
Author(s):  
Yu-Meng Lei ◽  
Miao Yin ◽  
Mei-Hui Yu ◽  
Jing Yu ◽  
Shu-E Zeng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Artificial Intelligence ◽  
Medical Imaging ◽  
Malignant Tumors ◽  
Cancer Risk Assessment ◽  
Physical And Mental Health ◽  
Early Screening ◽  
Daily Lives ◽  
Breast Cancer Risk Assessment

Artificial intelligence (AI) has invaded our daily lives, and in the last decade, there have been very promising applications of AI in the field of medicine, including medical imaging, in vitro diagnosis, intelligent rehabilitation, and prognosis. Breast cancer is one of the common malignant tumors in women and seriously threatens women’s physical and mental health. Early screening for breast cancer via mammography, ultrasound and magnetic resonance imaging (MRI) can significantly improve the prognosis of patients. AI has shown excellent performance in image recognition tasks and has been widely studied in breast cancer screening. This paper introduces the background of AI and its application in breast medical imaging (mammography, ultrasound and MRI), such as in the identification, segmentation and classification of lesions; breast density assessment; and breast cancer risk assessment. In addition, we also discuss the challenges and future perspectives of the application of AI in medical imaging of the breast.

scholarly journals SNPs for breast cancer risk assessment

Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 99211-99212 ◽  
Author(s):  
Jack Cuzick ◽  
Adam Brentnall ◽  
Mitchell Dowsett
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Breast Cancer Risk Assessment

scholarly journals Bayesian joint ordinal and survival modeling for breast cancer risk assessment

2016 ◽  
Vol 35 (28) ◽  
pp. 5267-5282 ◽  
Author(s):  
C. Armero ◽  
C. Forné ◽  
M. Rué ◽  
A. Forte ◽  
H. Perpiñán ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Breast Cancer Risk Assessment ◽  
Survival Modeling

scholarly journals Commentary ACOG Practice Bulletin July 2017: Breast Cancer Risk Assessment and Screening in Average-Risk Women

2018 ◽  
Vol 91 (1090) ◽  
pp. 20170907 ◽  
Author(s):  
Victoria Mango ◽  
Yolanda Bryce ◽  
Elizabeth Anne Morris ◽  
Elisabetta Gianotti ◽  
Katja Pinker
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Average Risk ◽  
Breast Cancer Risk Assessment

scholarly journals Breast cancer risk assessment: How risk models can “overdiagnose” risk.

2013 ◽  
Vol 31 (31_suppl) ◽  
pp. 184-184
Author(s):  
Elissa Ozanne ◽  
Brian Drohan ◽  
Kevin S. Hughes
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
High Risk ◽  
Resource Utilization ◽  
Management Strategies ◽  
Cancer Risk Assessment ◽  
Cancer Society ◽  
Total Study Population ◽  
Breast Cancer Risk Assessment ◽  
The Impact

184 Background: Overdiagnosis is commonly defined as a diagnosis of "disease" which will never cause symptoms or death during a patient's lifetime. Similarly, overdiagnosis can also happen when individuals are given the diagnosis of being at risk for a disease, such as being at high-risk for developing breast cancer. Women can be given such a diagnosis by meeting a set of risk assessment criteria, which are often accompanied by recommended management strategies. We sought to identify the extent and consequences of overdiagnosis for individuals being at high risk for breast cancer using the American Cancer Society (ACS) guidelines for the appropriate use of Magnetic Resonance Imaging (MRI). Methods: We identified women who fit the ACS criteria in a population based sample at a community hospital. The ACS criteria mentions three risk assessment models for determining a woman’s risk, and these criteria were reviewed to determine the extent of possible overdiagnosis in this population. The expected resource utilization resulting from this overdiagnosis, and the impact on patient quality of life are extrapolated. Results: 5,894 women who received mammography screening at the study site were included. 342 (5.8%) of the women were diagnosed as high risk by at least one model. However, only 0.2% of the total study population were diagnosed as high risk by all three models. One model identified 330 (5.6%) to be at high risk, while the other two models identified many fewer eligible women (25, 0.4% and 54, 0.9% respectively). Conclusions: Using different models to evaluation the ACS criteria identifies very different populations, implying a large potential for overdiagnosis. Further, this overdiagnosis is likely to result in the outcome of screening too many women, incurring false positives and unnecessary resource utilization.

scholarly journals Addressing Barriers to Uptake of Breast Cancer Chemoprevention for Patients and Providers

2015 ◽  
pp. e50-e58 ◽  
Author(s):  
Katherine D. Crew
Keyword(s):  
Breast Cancer ◽  
Primary Prevention ◽  
High Risk ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Chemoprevention ◽  
The United States ◽  
Cancer Risk Assessment ◽  
Breast Cancer Risk Assessment ◽  
Breast Cancer Chemoprevention

Breast cancer is the most common malignancy among women in the United States, and the primary prevention of this disease is a major public health issue. Because there are relatively few modifiable breast cancer risk factors, pharmacologic interventions with antiestrogens have the potential to significantly affect the primary prevention setting. Breast cancer chemoprevention with selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene, and with aromatase inhibitors (AIs) exemestane and anastrozole, is underutilized despite several randomized controlled trials demonstrating up to a 50% to 65% relative risk reduction in breast cancer incidence among women at high risk. An estimated 10 million women in the United States meet high-risk criteria for breast cancer and are potentially eligible for chemoprevention, but less than 5% of women at high risk who are offered antiestrogens for primary prevention agree to take it. Reasons for low chemoprevention uptake include lack of routine breast cancer risk assessment in primary care, inadequate time for counseling, insufficient knowledge about antiestrogens among patients and providers, and concerns about side effects. Interventions designed to increase chemoprevention uptake, such as decision aids and incorporating breast cancer risk assessment into clinical practice, have met with limited success. Clinicians can help women make informed decisions about chemoprevention by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of antiestrogens. Widespread adoption of chemoprevention will require a major paradigm shift in clinical practice for primary care providers (PCPs). However, enhancing uptake and adherence to breast cancer chemoprevention holds promise for reducing the public health burden of this disease.

scholarly journals The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing

2018 ◽  
Vol 2 (2) ◽  
pp. e24 ◽  
Author(s):  
Louisa L Lo ◽  
Ian M Collins ◽  
Mathias Bressel ◽  
Phyllis Butow ◽  
Jon Emery ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Assessment ◽  
Risk Management ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Management Tool ◽  
Breast Cancer Risk Assessment
Sign in / Sign up

Export Citation Format

Share Document